# Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

> **NCT01260727** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 92 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** PENNVAX-G DNA Vaccine
- **BIOLOGICAL:** MVA-CMDR Vaccine
- **BIOLOGICAL:** Placebo PENNVAX-G Vaccine
- **BIOLOGICAL:** Placebo MVA-CMDR Vaccine

## Key facts

- **NCT ID:** NCT01260727
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-12
- **Final completion:** 2015-06
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260727, "Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01260727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*